About Castle Creek Biosciences

Castle Creek Biosciences develops personalized gene therapies using autologous fibroblast technology to treat Dystrophic Epidermolysis Bullosa, a rare genetic skin disorder that causes severe blistering. Their approach aims to provide targeted relief for patients suffering from this debilitating condition by addressing the underlying genetic causes.

```xml <problem> Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disorder characterized by severe blistering, causing significant pain and complications for affected individuals. Current treatments offer limited relief, failing to address the underlying genetic defect responsible for the condition. </problem> <solution> Castle Creek Biosciences is developing personalized gene therapies for Dystrophic Epidermolysis Bullosa (DEB) using an autologous fibroblast technology platform. This approach involves collecting a patient's own skin cells (fibroblasts), genetically modifying them to correct the DEB-causing mutation, and then transplanting the corrected cells back into the patient's skin. The genetically corrected fibroblasts produce functional collagen, addressing the root cause of DEB and promoting wound healing and reducing blistering. This targeted gene therapy aims to provide long-term relief and improve the quality of life for individuals suffering from DEB. </solution> <features> - Autologous fibroblast technology utilizing patient's own cells to minimize immune rejection. - Ex-vivo gene editing to correct the mutated gene responsible for collagen production. - Targeted delivery of genetically modified fibroblasts to affected areas of the skin. - Production of functional collagen VII to restore skin integrity and reduce blistering. </features> <target_audience> The primary target audience includes patients diagnosed with Dystrophic Epidermolysis Bullosa (DEB) and their families, as well as physicians specializing in dermatology and genetic disorders. </target_audience> ```

What does Castle Creek Biosciences do?

Where is Castle Creek Biosciences located?

Castle Creek Biosciences is based in Euxton, United States.

When was Castle Creek Biosciences founded?

Castle Creek Biosciences was founded in 2015.

How much funding has Castle Creek Biosciences raised?

Castle Creek Biosciences has raised 344430000.

Location

Euxton, United States

Founded

2015

Funding

344430000

Employees

31 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Castle Creek Biosciences

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

castlecreekbio.com 3K+

Crunchbase

Founded 2015 – Euxton, United States

Funding

Estimated Funding

$200M+

Team (30+)

No team information available.

Company Description

Problem

Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disorder characterized by severe blistering, causing significant pain and complications for affected individuals. Current treatments offer limited relief, failing to address the underlying genetic defect responsible for the condition.

Solution

Castle Creek Biosciences is developing personalized gene therapies for Dystrophic Epidermolysis Bullosa (DEB) using an autologous fibroblast technology platform. This approach involves collecting a patient's own skin cells (fibroblasts), genetically modifying them to correct the DEB-causing mutation, and then transplanting the corrected cells back into the patient's skin. The genetically corrected fibroblasts produce functional collagen, addressing the root cause of DEB and promoting wound healing and reducing blistering. This targeted gene therapy aims to provide long-term relief and improve the quality of life for individuals suffering from DEB.

Features

Autologous fibroblast technology utilizing patient's own cells to minimize immune rejection.

Ex-vivo gene editing to correct the mutated gene responsible for collagen production.

Targeted delivery of genetically modified fibroblasts to affected areas of the skin.

Production of functional collagen VII to restore skin integrity and reduce blistering.

Target Audience

The primary target audience includes patients diagnosed with Dystrophic Epidermolysis Bullosa (DEB) and their families, as well as physicians specializing in dermatology and genetic disorders.